{
    "nctId": "NCT01091168",
    "briefTitle": "Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer",
    "officialTitle": "Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastases",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 594,
    "primaryOutcomeMeasure": "Overall Survival",
    "eligibilityCriteria": "Inclusion Criteria:(main conditions)\n\n* Female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy and who have received at least two prior chemotherapy regimens including anthracyclines,taxanes,antimetabolite and vinca-alkaloid and are no longer candidate for these drugs,\n* Karnofsky performance score of at least 70 %, adequate haematological, hepatic and renal functions and ECG without clinically relevant abnormality.\n\nExclusion Criteria:\n\n* Concurrent serious uncontrolled medical disorder,\n* known or clinical evidence of brain metastases or leptomeningeal involvement,\n* pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites,\n* history of second primary malignancy,\n* HIV infection, preexisting neuropathy,\n* pregnancy or breast feeding.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}